NASDAQ
ArriVent BioPharma, Inc. Common Stock (AVBP) has a free cash flow growth of -36.64% as of Friday, May 29, 2026. This represents a 48.05% increase compared to its 12-month average of -70.53%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.